Controlled comparison of amikacin and gentamicin

C. R. Smith, K. L. Baughman, C. Q. Edwards, J. F. Rogers, P. S. Lietman

Research output: Contribution to journalArticle

Abstract

Amikacin or gentamicin was used to treat 174 patients with suspected severe gram-negative infections in a prospective, randomized, double-blind trial. Enteric gram-negative bacilli were pathogenic in 71 cases (39 treated with amikacin, and 32 with gentamicin). Amikacin was effective in 10 of 12 bacteremias, 21 of 24 urinary-tract infections, two of five pneumonias and four of six other serious tissue infections. The total favorable response rate was 77% for amikacin and 78% for gentamicin. Nephrotoxicity and auditory toxicity could be evaluated in 124 and 67 cases respectively. Definite nephrotoxicity developed in five of 62 (8%) receiving amikacin and seven of 62 (11%) given gentamicin, and possible nephrotoxicity developed in four patients in both groups. Definite ototoxicity developed in two of 34 (6%) and three of 30 (10%) respectively. These differences were not statistically significant (by chi 2 analysis, P>0.05). The results indicate that amikacin is effective against severe gram-negative infections and is not more and not less ototoxic or nephrotoxic than gentamicin.

Original languageEnglish (US)
Pages (from-to)349-353
Number of pages5
JournalNew England Journal of Medicine
Volume296
Issue number7
StatePublished - 1977

Fingerprint

Amikacin
Gentamicins
Infection
Bacteremia
Urinary Tract Infections
Bacillus
Pneumonia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Smith, C. R., Baughman, K. L., Edwards, C. Q., Rogers, J. F., & Lietman, P. S. (1977). Controlled comparison of amikacin and gentamicin. New England Journal of Medicine, 296(7), 349-353.

Controlled comparison of amikacin and gentamicin. / Smith, C. R.; Baughman, K. L.; Edwards, C. Q.; Rogers, J. F.; Lietman, P. S.

In: New England Journal of Medicine, Vol. 296, No. 7, 1977, p. 349-353.

Research output: Contribution to journalArticle

Smith, CR, Baughman, KL, Edwards, CQ, Rogers, JF & Lietman, PS 1977, 'Controlled comparison of amikacin and gentamicin', New England Journal of Medicine, vol. 296, no. 7, pp. 349-353.
Smith CR, Baughman KL, Edwards CQ, Rogers JF, Lietman PS. Controlled comparison of amikacin and gentamicin. New England Journal of Medicine. 1977;296(7):349-353.
Smith, C. R. ; Baughman, K. L. ; Edwards, C. Q. ; Rogers, J. F. ; Lietman, P. S. / Controlled comparison of amikacin and gentamicin. In: New England Journal of Medicine. 1977 ; Vol. 296, No. 7. pp. 349-353.
@article{1b3a3394397045a5af2995fcc3d67db1,
title = "Controlled comparison of amikacin and gentamicin",
abstract = "Amikacin or gentamicin was used to treat 174 patients with suspected severe gram-negative infections in a prospective, randomized, double-blind trial. Enteric gram-negative bacilli were pathogenic in 71 cases (39 treated with amikacin, and 32 with gentamicin). Amikacin was effective in 10 of 12 bacteremias, 21 of 24 urinary-tract infections, two of five pneumonias and four of six other serious tissue infections. The total favorable response rate was 77{\%} for amikacin and 78{\%} for gentamicin. Nephrotoxicity and auditory toxicity could be evaluated in 124 and 67 cases respectively. Definite nephrotoxicity developed in five of 62 (8{\%}) receiving amikacin and seven of 62 (11{\%}) given gentamicin, and possible nephrotoxicity developed in four patients in both groups. Definite ototoxicity developed in two of 34 (6{\%}) and three of 30 (10{\%}) respectively. These differences were not statistically significant (by chi 2 analysis, P>0.05). The results indicate that amikacin is effective against severe gram-negative infections and is not more and not less ototoxic or nephrotoxic than gentamicin.",
author = "Smith, {C. R.} and Baughman, {K. L.} and Edwards, {C. Q.} and Rogers, {J. F.} and Lietman, {P. S.}",
year = "1977",
language = "English (US)",
volume = "296",
pages = "349--353",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "7",

}

TY - JOUR

T1 - Controlled comparison of amikacin and gentamicin

AU - Smith, C. R.

AU - Baughman, K. L.

AU - Edwards, C. Q.

AU - Rogers, J. F.

AU - Lietman, P. S.

PY - 1977

Y1 - 1977

N2 - Amikacin or gentamicin was used to treat 174 patients with suspected severe gram-negative infections in a prospective, randomized, double-blind trial. Enteric gram-negative bacilli were pathogenic in 71 cases (39 treated with amikacin, and 32 with gentamicin). Amikacin was effective in 10 of 12 bacteremias, 21 of 24 urinary-tract infections, two of five pneumonias and four of six other serious tissue infections. The total favorable response rate was 77% for amikacin and 78% for gentamicin. Nephrotoxicity and auditory toxicity could be evaluated in 124 and 67 cases respectively. Definite nephrotoxicity developed in five of 62 (8%) receiving amikacin and seven of 62 (11%) given gentamicin, and possible nephrotoxicity developed in four patients in both groups. Definite ototoxicity developed in two of 34 (6%) and three of 30 (10%) respectively. These differences were not statistically significant (by chi 2 analysis, P>0.05). The results indicate that amikacin is effective against severe gram-negative infections and is not more and not less ototoxic or nephrotoxic than gentamicin.

AB - Amikacin or gentamicin was used to treat 174 patients with suspected severe gram-negative infections in a prospective, randomized, double-blind trial. Enteric gram-negative bacilli were pathogenic in 71 cases (39 treated with amikacin, and 32 with gentamicin). Amikacin was effective in 10 of 12 bacteremias, 21 of 24 urinary-tract infections, two of five pneumonias and four of six other serious tissue infections. The total favorable response rate was 77% for amikacin and 78% for gentamicin. Nephrotoxicity and auditory toxicity could be evaluated in 124 and 67 cases respectively. Definite nephrotoxicity developed in five of 62 (8%) receiving amikacin and seven of 62 (11%) given gentamicin, and possible nephrotoxicity developed in four patients in both groups. Definite ototoxicity developed in two of 34 (6%) and three of 30 (10%) respectively. These differences were not statistically significant (by chi 2 analysis, P>0.05). The results indicate that amikacin is effective against severe gram-negative infections and is not more and not less ototoxic or nephrotoxic than gentamicin.

UR - http://www.scopus.com/inward/record.url?scp=0017344468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017344468&partnerID=8YFLogxK

M3 - Article

C2 - 319355

AN - SCOPUS:0017344468

VL - 296

SP - 349

EP - 353

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 7

ER -